中国2004—2010艾滋病母婴传播率及母婴阻断药物应用状况的系统评价

目的:了解我国2004-2010年艾滋病母婴传播及母婴阻断药物应用状况。方法：全面检索CBM和Pubmed等中英文数据库，检索时间均从建库到2013年5月。对纳入的文献采用参照AHRQ横断面研究评价标准和STROBE声明拟定的四条标准进行质量评价。并将样本量、监测地点和监测年份作为主要异质性来源进行meta回归分析。采用Comprehensive Meta-Analysis V2.0 software 进行meta分析。结果：共检索到文献2356篇，最终纳入51篇进行分析。2004-2010年我国艾滋病母婴传播率依次分别为12.90%（95% CI: 7.48 %- 21.36%），16.35%（95% CI: 10.41%- 24.73%），6.45%（95% CI: 3.73 %- 10.93%），6.25%（95% CI: 2.39%- 15.36%），5.56%（95% CI: 2.79 %- 10.76%），3.10%（95% CI: 1.59 %- 5.97%），2.29%（95% CI: 1.36 %- 3.83%）。2004-2010年，我国艾滋病孕产妇中阻断药物应用率依次分别为70.39%（95% CI: 24.42%-94.59%），71.99%（95% CI: 61.49%-80.54%），78.79%（95% CI: 70.19%-85.43%），86.84%（95% CI: 79.24%-91.94%），82.71%（95% CI: 76.62%-87.48%），81.85%（95% CI: 75.55%-86.80%），86.16%（95% CI: 53.20%-97.15%）。2005-2010年婴儿阻断药物应用率依次分别为80.72%（95%CI: 72.89%-86.70%），81.84%（95% CI:71.55%-88.98%），85.43%（95% CI:80.99%-88.97%）,89.75%（95% CI: 81.82%-94.45%）,92.39%（95% CI: 84.97%-96.31%），90.34%（95% CI: 85.50%-93.68%）。结论：近年来我国艾滋病母婴传播率呈下降趋势，孕产妇及婴儿阻断药物应用率都有所升高。

Mother-to-child transmission rate of HIV and use of drugs to prevent the transmission in China: a systematic review

Objective To understand the mother-to-child transmission rate of human immunodeficiency virus (HIV) and the use of drugs to prevent the transmission in China from 2004 to 2010. Methods English and Chinese databases including PubMed, Chinese Biomedical Literature database (CBM), etc. were searched to retrieve the relevant references from the start to May 2013. Quality evaluation of the included studies was performed with four criteria which was compiled according to AHRQ cross-sectional study evaluation standards and the STROBE statement. The sample size, recruitment venue and study year were taken as the main source of heterogeneity in meta regression analysis. The data was analyzed by Comprehensive Meta-Analysis V2.0 software. Results A total of 2 356 references were retrieved, and 51 of them were finally included in meta-analysis. In 2004-2010, the mother-to-child transmission rates of HIV were 12.90%(95% CI: 7.48%-21.36%),16.35%(95% CI: 10.41%-24.73%),6.45%(95% CI: 3.73%-10.93%),6.25%(95% CI: 2.39%-15.36%),5.56%(95% CI: 2.79%-10.76%),3.10%(95% CI: 1.59%-5.97%), and 2.29%(95% CI: 1.36%-3.83%), respectively. Meanwhile, From 2004 to 2010, the drug use rates for HIV antiretroviral prophylaxis among pregnant women were 70.39%(95% CI: 24.42%-94.59%),71.99%(95% CI: 61.49%-80.54%),78.79%(95% CI: 70.19%-85.43%), 86.84%(95% CI: 79.24%-91.94%), 82.71%(95% CI: 76.62%-87.48%), 81.85%(95% CI: 75.55%-86.80%), and 86.16%(95% CI: 53.20%-97.15%), respectively. And in 2005-2010, the drug use rates for HIV antiretroviral prophylaxis among infants were 80.72%(95%CI: 72.89%-86.70%), 81.84%(95% CI:71.55%-88.98%), 85.43%(95% CI: 80.99%-88.97%), 89.75%(95% CI: 81.82%-94.45%), 92.39%(95% CI: 84.97%-96.31%), and 90.34%(95% CI: 85.50%-93.68%), respectively. Conclusion The HIV mother-to-child transmission rate is decreasing in China in recent years, and the drug use rates of HIV antiretroviral prophylaxis are increasing among HIV-infected pregnant women and their infants.